Filing Details

Accession Number:
0001209191-22-032330
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-05-26 18:31:41
Reporting Period:
2022-05-24
Accepted Time:
2022-05-26 18:31:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1457612 Genocea Biosciences Inc. GNCA Biological Products, (No Disgnostic Substances) (2836) 510596811
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1559807 W. Peter Sonsini 2855 Sand Hill Road
Menlo Park CA 94025
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-05-24 5,931,843 $0.07 4,445,093 No 4 S Indirect See Note 2
Common Stock Disposition 2022-05-25 4,445,093 $0.08 0 No 4 S Indirect See Note 2
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Note 2
No 4 S Indirect See Note 2
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.060 to$0.0746, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities andExchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth inthis footnote (1) to this Form 4.
  2. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 16 in which the Reporting Person has no pecuniary interest.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.0675 to $0.0980, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.